FGFR2 and gastric adenocarcinoma: Moreover, FGFR2 high-expression (P = 0.031, 5-year survival rate: 52.2% vs. 35.9%) (Figure 2G) and SPRY2 low-expression (P = 0.020, 5-year survival rate: 43.2% vs. 61.3%) (Figure 2H) were also demonstrated to be biomarkers for poorer prognosis in gastric adenocarcinoma.